E Fund Management Co. Ltd. Sells 7,226 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

E Fund Management Co. Ltd. decreased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 30.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,612 shares of the biotechnology company’s stock after selling 7,226 shares during the quarter. E Fund Management Co. Ltd.’s holdings in BioCryst Pharmaceuticals were worth $125,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Venturi Wealth Management LLC bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $46,000. R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth approximately $48,000. KBC Group NV boosted its holdings in BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 4,537 shares during the period. Raymond James Financial Inc. purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $80,000. Finally, Quantinno Capital Management LP bought a new position in shares of BioCryst Pharmaceuticals in the third quarter worth $82,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on BCRX shares. Wedbush initiated coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective for the company. JMP Securities reiterated a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Needham & Company LLC lifted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $11.00 price target (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $7.69 on Monday. The firm has a market cap of $1.61 billion, a P/E ratio of -12.61 and a beta of 1.85. The business’s 50 day moving average price is $8.15 and its 200-day moving average price is $7.87. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same quarter in the prior year, the firm posted $0.28 earnings per share. The company’s revenue for the quarter was up 40.8% on a year-over-year basis. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.